AKTX צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Akari Therapeutics plc

Akari Therapeutics (AKTX) develops high-precision treatments for rare immune pathologies by targeting proteins. The scientific community's high level of confidence in these developments drives the current quarterly EPS pace on the GURU.Markets chart, where 79.40 is the current level of the indicator. Unique patents provide the foundation for the company's stability, guaranteeing long-term royalties and a high-quality inflow of free cash flow.
AKTX (akaritx.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The operational successes of Akari Therapeutics (AKTX) in developing immune drugs are reflected in the quarter-over-quarter EPS dynamics, which visualize the rate of change in net profit per share. This metric measures the efficiency of intellectual property capitalization, allowing investors to assess the biotech startup's transition from costly research to highly scalable profit extraction through mass drug production.